Replies to post #159933 on Biotech Values

[biomaven0]

somewhat of a disconnect between AGN’s prior statement that Levadex will have peak annual sales of $500M (#msg-83735072) and AGN’s saying today that there is no need to reduce 2013 EPS guidance for the CRL.

Maybe not, given first year sales (for a partial year to boot) would be way less than peak sales. Just guessing here, but maybe $25m in FY13 sales would have been realistic and there would have been associated marketing and sampling costs as well. So EPS likely not materially impacted either way.

AGN could clearly have gotten the company cheaper if they had waited for this second CRL. Shows just how long it can take to fix an FDA issue at a small contract manufacturer.

Peter